← USPTO Patent Grants

MMLV reverse transcriptase variants

Grant US12577545B2 Kind: B2 Mar 17, 2026

Assignee

10X GENOMICS, INC.

Inventors

Josephine Lee, Samuel Marrs, Geoffrey McDermott, Francesca Meschi, Luz Montesclaros, Katherine Pfeiffer, Joseph Francis Shuga, Jessica Michele Terry, Solongo B. Ziraldo

Abstract

Disclosed herein, are compositions, methods, and kits comprising engineered reverse transcription enzymes that exhibit several desired properties such as thermal stability, processive reverse transcription, non-templated base addition, and template switching ability. The engineered reverse transcription enzymes described herein demonstrate unexpectedly higher resistance to cell lysate inhibition, greater ability to capture full-length mRNA transcripts, and demonstrate improved results in small reaction volumes as compared to other engineered reverse transcription enzymes.

CPC Classifications

C12N 9/12 C12N 9/1276 C12N 15/10

Filing Date

2020-12-07

Application No.

17114016

Claims

10